Clinical implications of lncRNA LINC-PINT in cancer

Ihtisham Bukhari; Muhammad Riaz Khan; Fazhan Li; Bartlomiej Swiatczak; Rick Francis Thorne; Pengyuan Zheng; Yang Mi

doi:10.3389/fmolb.2023.1097694

Clinical implications of lncRNA LINC-PINT in cancer

Front Mol Biosci. 2023 Mar 17:10:1097694. doi: 10.3389/fmolb.2023.1097694. eCollection 2023.

Authors

Ihtisham Bukhari¹, Muhammad Riaz Khan², Fazhan Li¹, Bartlomiej Swiatczak³, Rick Francis Thorne⁴, Pengyuan Zheng¹, Yang Mi¹

Affiliations

¹ Henan Key Laboratory of Helicobacter pylori, Microbiota and Gastrointestinal Cancer, Marshall Medical Research Center, Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
² Research Center on Aging, Centre Intégré Universitaire de Santé et Services Sociaux de l'Estrie-Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada.
³ Department of History of Science and Scientific Archeology, University of Science and Technology of China, Hefei, China.
⁴ School of Environmental and Life Sciences, The University of Newcastle, Callaghan, NSW, Australia.

Abstract

Long noncoding RNAs (lncRNAs) possess the potential for therapeutic targeting to treat many disorders, including cancers. Several RNA-based therapeutics (ASOs and small interfering RNAs) have gained FDA approval over the past decade. And with their potent effects, lncRNA-based therapeutics are of emerging significance. One important lncRNA target is LINC-PINT, with its universalized functions and relationship with the famous tumor suppressor gene TP53. Establishing clinical relevance, much like p53, the tumor suppressor activity of LINC-PINT is implicated in cancer progression. Moreover, several molecular targets of LINC-PINT are directly or indirectly used in routine clinical practice. We further associate LINC-PINT with immune responses in colon adenocarcinoma, proposing the potential utility of LINC-PINT as a novel biomarker of immune checkpoint inhibitors. Collectively, current evidence suggests LINC-PINT can be considered for use as a diagnostic/prognostic marker for cancer and several other diseases.

Keywords: Cancer biomarkers; Cancer therapy; Colon adenocarcinoma (CAC); Immune checkpoint inhibitors; LINC-PINT; LncRNA; PINTology.

Grants and funding

This work was supported by Zhengzhou Major Collaborative Innovation Project (No.18XTZX12003); Key projects of discipline construction in Zhengzhou University (No. XKZDJC202001); National Key Research and development program in China (No.2020YFC2006100); Medical service capacity improvement project of Henan Province in China (grant number Yu Wei Medicine [2017] No.66).